ABUS
- Arbutus Biopharma Corporation
()
Overview
Company Summary
Arbutus Biopharma Corporation (ABUS) is a biopharmaceutical company that focuses on discovering, developing, and commercializing innovative therapies to treat patients suffering from chronic Hepatitis B (HBV) infection. HBV is a potentially life-threatening viral infection that affects the liver and can lead to cirrhosis, liver cancer, and other complications.
ABUS specializes in the development of direct-acting antiviral agents (DAAs) that target HBV replication, aiming to cure patients by eliminating the virus from their bodies. Their approach involves a combined therapy of multiple drug candidates, including small molecules and RNA interference (RNAi) technologies, which work synergistically to inhibit viral replication through different mechanisms.
The company's broad portfolio of clinical-stage drug candidates includes both oral and injectable therapies. These candidates are designed to improve upon current treatment options by increasing efficacy, reducing side effects, and achieving a durable response with a finite treatment duration.
In addition to its core focus on HBV, Arbutus Biopharma also has ongoing research and development efforts in related areas such as other viral infections, including Hepatitis D (HDV), as well as viral-based gene therapies and RNAi therapeutics.
ABUS collaborates with academic institutions, industry partners, and government agencies to leverage scientific expertise and advance its pipeline of innovative therapies. Through strategic partnerships and licensing agreements, the company aims to maximize the potential of its technologies and expand its reach globally.
Overall, Arbutus Biopharma Corporation is dedicated to developing breakthrough treatments for chronic HBV infection and related diseases, with the ultimate goal of improving the lives of patients worldwide.